Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2021-03-16 14:55 (741 d 06:59 ago) – Posting: # 22271
Views: 1,970

Hi dshah,

❝ I am having few doubts for harmonization.

Welcome to the club!

❝ Why regulatory bodies does have different requirement for scaling acceptance …

IMHO, not related to science at all but to politics.
I attended all conferences of the ‘Global Bioequivalence Harmonization Initiative’ and was a member of the panel of the session ‘Scaling Procedure and Adaptive Design(s) in BE Assessment of Highly Variable Drugs’ (2nd GBHI, Rockville, September 2016). Justifications? Not really. I guess (‼):

❝ Or for NTI- limit of 90.00-111.11 is more relevant than RSABE approach and does justify the safety and efficacy?

Good question, next question.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,553 posts in 4,724 threads, 1,606 registered users;
21 visitors (0 registered, 21 guests [including 6 identified bots]).
Forum time: 22:55 CEST (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz